Patent ID: 7087212

Claim:
A method of targeting an effector molecule to a target site in a patient, said method comprising: providing to said patient an effective amount of a physiologically acceptable composition comprising an organized mobile multicomponent conjugate (OMMC) assembly comprising a lamellar structure selected from at least one of salts of docosanoic acid or salts of octacosanoic acid; said lamellar structure defining a void and having incorporated at least two binding compounds B 1 and B 2 independently selected from at least one of amino acids, peptides (1–20 amino acids), peptidomimics, monosaccharides, oligosaccharides (1–10), glycomimics, glycopeptides, anionic compounds, C- or O-monosaccharides and glycosides, flavonoids, isoflavonones, or C- or O-glucosides; B 1 bound to said structure by anchor region A 1 and B 1 and A 1 linked via linker L 1 wherein A 1 is a succinic acid ester of PEG[50] stearate L 1 and B 2 bound to said structure by anchor region A 2 and B 2 and A 2 linked via linker L 2 wherein A 2 is a fucosuccinamide ester of a PEG[50] stearate L 2 , and an effector molecule selected from an echogenic agent selected from the group consisting of perfluoropropane, perfluorobutane, sulfur hexafluoride, tetrafluoromethane, hexafluoroethane, octafluoropropane, decafluorbutane , dodecafluorpentane, and perfluorohexane; a radionuclide selected from the group consisting of I-123, I-131, Tc-99m, Re-186, Re-188, Sm-152, Ho-155, Bi-202, and Lu-157; a paramagnetic agent selected from the group consisting of Gd-DTPA, Gd-DOTA, Gd-DTPA-bis(methoxyethyl)amide, and Mn-EDTA; a cytotoxcic agent selected from the group consisting of fluorouracil, fluorouridine, sulfisoxazole, N′-(w-thiazolyl)sulfanilamide, sulfmethoxazole, and sulfisomidine; and an optical agent selected from the group consisting of fluorescein and indocyanine green, said B 1 and B 2 binding to at least first and second affinity sites in said target site, wherein a position of B 1 and B 2 relatively self-adjust to form an OMMO ensemble resulting in cooperative binding of B 1 and B 2 to said affinity sites, wherein said effector molecule is provided to the target site.